Developing inhibitory peptides against SARS-CoV-2 envelope protein

Area of Science:

• Virology
• Drug Discovery
• Molecular Biology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, poses a significant global health challenge.
• High mutation rates in SARS-CoV-2 complicate prevention and treatment strategies.
• The conserved Envelope (E) protein across human coronaviruses presents a potential therapeutic target.

Purpose of the Study:

• To develop and characterize novel inhibitory peptides targeting the SARS-CoV-2 Envelope (E) protein.
• To evaluate the therapeutic potential of these peptides against SARS-CoV-2 infection.
• To explore the adaptability of these peptides for other human coronaviruses.

Main Methods:

• Development of screening platforms based on E protein-induced alterations in proton homeostasis and NFAT/AP-1 pathways.
• Design and optimization of inhibitory peptides (iPep-SARS2-E) against SARS-CoV-2 E protein.
• In vitro and in vivo testing using cell cultures (Vero-E6), lung organoids, and mouse models.

Main Results:

• iPep-SARS2-E significantly inhibits SARS-CoV-2 virus egress.
• The peptide reduces viral cytotoxicity and propagation in both in vitro and in vivo models.
• The developed peptide strategy is customizable for other human coronaviruses, including MERS-CoV.

Conclusions:

• The SARS-CoV-2 Envelope (E) protein is a viable therapeutic target for developing antiviral strategies.
• iPep-SARS2-E demonstrates significant potential for inhibiting SARS-CoV-2 and related coronaviruses.
• Targeting the conserved E protein offers a promising avenue for broad-spectrum coronavirus therapeutics.